# Rituximab for Autoimmune Retinopathy

> **NCT01086631** · PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 5 (actual)

## Conditions studied

- Autoimmune Disease

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01086631
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-22
- **Primary completion:** —
- **Final completion:** 2014-07-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2018-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01086631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01086631, "Rituximab for Autoimmune Retinopathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01086631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*